Salvage SBRT for Previously Irradiated Lung Cancer

Steven K. Seung1,2*, Matthew Solhjem1

1The Oregon Clinic, Portland, USA; 2The Earle A. Chiles Research Institute, Portland, USA.

Received April 23rd, 2011; revised May 24th, 2011; accepted May 31st, 2011.

ABSTRACT

Purpose: Patients with locally recurrent lung cancer after definitive radiation therapy pose a challenge in management. Surgery is often not an option and chemotherapy offers poor long-term local control. Stereotactic body radiotherapy (SBRT) was investigated in an attempt to salvage locally recurrent lung cancer. Materials and Methods: From March, 2009 to January, 2010, 8 patients who had previous definitive radiation therapy for lung cancer at least six months prior to the diagnosis of locally recurrent disease underwent SBRT. Local recurrence was documented by CT, PET, and/or biopsy. Patients had to have Karnofsky Performance Score (KPS) > 70, no distant metastases by CT/PET and brain MRI, and lesions amenable to SBRT. SBRT dose deliveries were 12 Gy x 4, 10 Gy x 5, 8 Gy x 5, or 20 Gy x 3 at the treating physician’s discretion. No adjuvant chemotherapy was delivered. Results: Eight patients were included in this study. Patient characteristics were: 6 females and 2 males; ages 50 - 85 (median 71); KPS 70 - 100 (median 80); previous stage I (T1/2 N0) in 4 and stage II/III (T1/2 N1/N2) in 3, 1 pt had limited stage small cell; previous radiation doses 50 - 68 Gy in 1.8/2.5 Gy fractions; time interval from previous RT to SBRT 8 - 57 months (median 36 months); target lesion diameters 1.2 - 7.3 cm (median 4.5 cm). With a median FU of 18 months (11 - 20 months), 7 patients are alive. Crude local/regional control to date is 86% with distant metastases in 1/7 surviving patients. Acute pulmonary toxicities: cough grade 0 7/8, grade 1 1/8; pain grade 0 6/8, grade 1 2/8; dyspnea grade 2 8/8. 1 patient died 12 months after SBRT due to complications from a hip fracture. Her disease was locally controlled at the time of death. Discussion: In carefully selected patients who recur locally after previous conventional radiation therapy for lung cancer, SBRT can offer a well tolerated salvage therapy. Further follow up is needed to assess long-term local control, survival and toxicities.

Keywords: SBRT, Lung Cancer, Re-Irradiation

1. Introduction

Conventional radiotherapy yields local control rates in the range from 40% to 70% and 5-year survival in the range from 10% to 30%. [1-3] In addition, conventional radiotherapy is performed via a protracted treatment course, typically six weeks, which consumes the precious commodity of time remaining for the patients. When these patients recur within the radiation field as the only site if disease, the standard of care has been to offer salvage chemotherapy or supportive care, as surgery is often a poor option. However, second-line chemotherapy does not produce durable responses. [4] Re-irradiation with conventional radiation has been reported as well with variable success. [5-9]

Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) have become routine treatment options for patients with brain metastases. [10-15] High fractional dose is more effective for radiation resistant cells. This is suggested by the good local control seen in hypofractionated radiation therapy for nodal metastases and radiosurgery for brain metastases in melanoma. [16-18] However, the risk of long-term normal tissue complication is correlated with the fraction size. The tight conformality (and thus the avoidance of normal tissue) possible with radiosurgical techniques permits safer delivery of single doses in the range of 15 - 20 Gy. Using prototypes for image-guided radiation therapy (IGRT) [19], stereotactic body radiotherapy (SBRT) which mimics SRT for extracranial disease, e.g., small sized lung cancers, has been reported where hypofractionated therapy in fractional doses of 12 - 20 Gy appeared to be relatively safe and effective resulting in local control rates of 80% - 90% [20].
The translation of SRS and SRT to extracranial sites was limited by two problems. First, tumors in the body are subject to motion related to natural physiological process like breathing and digestion. Second, because the treatments are highly focused, image guidance needed to be such that the selected patients are properly treated with limited fields and that the target extent can be determined accurately. By the early 1990s, technological advances in both tumor motion tracking and image guidance allowed the concepts of SRS and SRT to be extended to extracranial sites where it is now known as SBRT. The American College of Radiology and the American Society of Therapeutic Radiology and Oncology have published guidelines that define SBRT and its proper conduct. [21] Patients selected for SBRT should have a limited number of demarcated tumors whose extent can be identified directly on treatment-planning image platforms or reliably fused by image registration techniques. Some method of tumor motion control must be used to avoid large margin treatments.

SBRT is an ablative therapy, and it should be understood that targeted tissue is likely to be destroyed. Many beams are brought in from multiple directions so that entrance dose is spread out. Beams are shaped to achieve conformality and rapid dose fall-off. The SBRT dosimetry approach is borrowed from intracranial SRS in which treatments have been well tolerated with long term follow-up. [22]

SBRT for lung tumors has been promising. [23-26] Onishi et al. reported overall local control rate of 92% for patients who received SBRT with a biologic equivalent dose (BED) greater than 100 Gy and 74% for those with a BED less than 100 Gy. [27] Among those who were medically operable but instead underwent SBRT, the 3-year overall survival rate was 88% if the patients received a BED greater than 100 Gy.

Based on these encouraging data demonstrating excellent local control and a relatively low risk of acute and late side effects, we treated patients who recurred locally after previous definitive conventional radiation therapy using SBRT alone. The primary endpoints were to assess local control and acute toxicities, and the secondary endpoints were to determine survival, late toxicities and distant metastases.

2. Patients and Methods

Eligibility criteria included tumors ≤ 7.0 cm at the time of evaluation for recurrence, time interval from previous radiation to recurrence ≥ 6 months, age older than 18 years, Karnofsky performance status ≥ 70, histologic or radiographic confirmation of active malignancy by fluorodeoxyglucose (FDG) positron emission tomography (PET), and absence of metastatic disease by chest computed tomography (CT)/PET and brain MRI. Previous diagnosis of limited stage small cell lung cancer was allowed. All patients were evaluated by a multidisciplinary team (thoracic surgery, radiation oncology, and medical oncology) and informed consent was obtained before treatment.

Four-dimensional CT scan was performed with the patient in the treatment position immobilized with the BodyFIX® (Elekta, Atlanta, GA). The internal tumor volume (ITV) was delineated on the lung window of the planning CT scan. A 3 - 5 mm planning target volume (PTV) margin was used to account for intrafraction tumor motion. A radiosurgical intensity modulated radiation therapy treatment plan with 6 MV photons was generated using Pinnacle v.9.0 software (Philips Medical Systems, Andover, MA) based on tumor location and geometry. Treatment was delivered on the Synergy S® (Elekta, Atlanta, GA) with the target localized with cone beam CT (CBCT) prior to each treatment delivery. The dose prescription was at the discretion of the treating physician; however, 90% of the PTV had to be covered by 99% of the prescribed dose. The normal tissue constraints in this situation are unknown. We therefore elected to follow the normal tissue constraint guidelines for RTOG 0813 (phase I/II study for SBRT for early stage, centrally located, nonsmall cell lung cancer, (http://www.rtog.org/members/protocols/0813/0813.pdf) understanding the uncertainties of valid applicability given our differing dosing patterns and the patients’ previous radiation treatments.

Adjuvant chemotherapy was not given as the role of chemotherapy after salvage SBRT for locally recurrent non-small cell lung cancer is undefined. As for the patient with locally recurrent small cell lung cancer, since the only measurable disease was treated with SBRT, chemotherapy was not given until disease progression was documented. Patients were followed post SBRT with an initial repeat CT scan at two months, then repeat CT scans every 3 months. PET scan was repeated if indicated clinically and radiographically to confirm recurrence.

3. Results

3.1. Patient Characteristics

From March, 2009 to January, 2010, 8 patients who had previous definitive radiation therapy for stage I-III non-small cell or limited stage small cell lung cancer at least six months prior to the diagnosis of locally recurrent disease were evaluated for this study. Local recurrence was documented by PET and/or biopsy. SBRT dose deliveries were 12 Gy × 4, 10 Gy × 5, 8 Gy × 5, or 20 Gy × 3 at the treating physician’s discretion. No adjuvant chemotherapy was delivered.

Copyright © 2011 SciRes.
Patient characteristics were: 6 females and 2 males; ages 50 - 85 (median 71); KPS 70 - 100 (median 80); previous stage I (T1/2 N0) in 4 and stage II/III (T1/2 N1/N2) in 3, 1 pt had limited stage small cell; previous radiation doses 50 - 68 Gy in 1.8/2.5 Gy fractions; time interval from previous RT to SBRT 8 - 57 months (median 36 months); target lesion diameters 1.2 - 7.3 cm (median 4.5 cm).

3.2. Treatment Outcomes

With a median follow-up (FU) of 18 months (11-20 months), 7 patients are alive. Local/regional control to date is 6/7 (86%) with distant metastases in 1/7 surviving patients. An example of a patient’s response is shown in Figure 1. The patient with the history of limited stage small cell who received 8 Gy × 5 (BED 70) recurred locally at 11 months as confirmed by a repeat PET scan. This patient went on to receive second-line chemotherapy. To date, the sole distant metastasis was seen in the contra-lateral lung at 12 months from SBRT in patient 3 (Table 1). Due to the small patient numbers, only the crude survival data are shown in Table 1.

Acute pulmonary toxicities (common toxicity criteria [CTC] v. 4) were relatively mild (Table 2). Seven out of

Table 1. Patient characteristics.

<table>
<thead>
<tr>
<th>Pt. No.</th>
<th>Age</th>
<th>Sex</th>
<th>KPS</th>
<th>Prev stage</th>
<th>Prev RT dose (Total Gy/fx Gy)</th>
<th>Interval prev RT to SBRT (mos)</th>
<th>Location in lung</th>
<th>Lesion dia (cm)</th>
<th>SBRT dose (Gy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>78</td>
<td>F</td>
<td>90</td>
<td>T1N0</td>
<td>68/2</td>
<td>48</td>
<td>LLL</td>
<td>2.1</td>
<td>12 × 4</td>
</tr>
<tr>
<td>2</td>
<td>85</td>
<td>F</td>
<td>70</td>
<td>T1N0</td>
<td>55/2.5</td>
<td>36</td>
<td>RUL</td>
<td>7.3</td>
<td>12 × 4</td>
</tr>
<tr>
<td>3</td>
<td>65</td>
<td>M</td>
<td>80</td>
<td>T2N0</td>
<td>68/2</td>
<td>37</td>
<td>RLL</td>
<td>6.3</td>
<td>10 × 5</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
<td>M</td>
<td>70</td>
<td>T2N1</td>
<td>63/1.8</td>
<td>57</td>
<td>RUL</td>
<td>4.5</td>
<td>10 × 5</td>
</tr>
<tr>
<td>5</td>
<td>74</td>
<td>F</td>
<td>100</td>
<td>T1N0</td>
<td>66/2</td>
<td>24</td>
<td>LUL</td>
<td>1.2</td>
<td>20 × 3</td>
</tr>
<tr>
<td>6</td>
<td>81</td>
<td>F</td>
<td>80</td>
<td>T2N1</td>
<td>60/2.5</td>
<td>15</td>
<td>RUL</td>
<td>5.1</td>
<td>10 × 5</td>
</tr>
<tr>
<td>7</td>
<td>50</td>
<td>F</td>
<td>100</td>
<td>T2N2</td>
<td>60/2</td>
<td>8</td>
<td>RUL</td>
<td>2.7</td>
<td>8 × 5</td>
</tr>
<tr>
<td>8</td>
<td>68</td>
<td>F</td>
<td>90</td>
<td>Limited small cell</td>
<td>50/2</td>
<td>38</td>
<td>RLL</td>
<td>4.6</td>
<td>8 × 5</td>
</tr>
</tbody>
</table>

Table 2. Patient outcomes.

<table>
<thead>
<tr>
<th>Pt. No.</th>
<th>FU (mos)</th>
<th>LC</th>
<th>Alive</th>
<th>Cause of death</th>
<th>Regional/ Distant recurrence</th>
<th>Acute side effects &lt; grade 3</th>
<th>Late effects &lt; grade 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>Mild SOB</td>
<td>Cough, SOB</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>Mild SOB</td>
<td>SOB</td>
</tr>
<tr>
<td>3</td>
<td>18</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>Y at 12 mos in contra lateral lung</td>
<td>Mild SOB</td>
<td>Cough, back pain</td>
</tr>
<tr>
<td>4</td>
<td>19</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>Mild SOB, Mild dysphagia, Rash</td>
<td>SOB</td>
</tr>
<tr>
<td>5</td>
<td>18</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>Mild SOB, Chest pains</td>
<td>SOB</td>
</tr>
<tr>
<td>6</td>
<td>14</td>
<td>N</td>
<td>Complications from hip fx</td>
<td>N</td>
<td>N</td>
<td>Mild SOB, Fatigue</td>
<td>SOB</td>
</tr>
<tr>
<td>7</td>
<td>13</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>Mild SOB, Tachycardia</td>
<td>SOB</td>
</tr>
<tr>
<td>8</td>
<td>11</td>
<td>N at 11 mos</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>Mild SOB</td>
<td>SOB</td>
</tr>
</tbody>
</table>
therapy was not given upfront since adjuvant chemotherapy during or after SBRT. Chemotherapy, depending on the tumor size and location, and none of the patients received chemotherapy. In our study, the patients were treated with a single-fraction SBRT for lung tumors.[28] They reported the efficacy and toxicity of SBRT in patients who locally recurred after previous definitive radiation therapy. The main rationale for using SBRT was for its ability to yield excellent local control and relative low toxicities. With hypofractionated SBRT as performed in this study, we observed no treatment-related deaths. Le et al. included 6 patients (out of 32) who had prior radiation therapy and who received prior thoracic radiation. Eighteen patients were 25-Gy dose in a single fraction resulted in significant toxicity in patients who had received prior thoracic radiotherapy. Two of their presumed treatment-related deaths were in such patients. The other factor that appeared to be associated with increased treatment-related toxicity was the use of prior or post treatment chemotherapy. In our study, the patients were treated with a variety of hypofractionation schemes, rather than a single dose, depending on the tumor size and location, and none received chemotherapy during or after SBRT. Chemotherapy was not given upfront since adjuvant chemotherapy after re-irradiation of a solitary recurrence is not defined. In addition, there were no additional lesions to follow to see the effects of chemotherapy. Chemotherapy, however, was offered to the one patient who developed multiple bilateral lung metastases 15 months after his SBRT salvage.

Recently Kelly et al. reported the M.D. Anderson experience of SBRT for patients with lung cancer previously undergoing thoracic radiation.[29] In this study, 11 out of 36 patients had in-field local recurrence prior to SBRT as in our study. Their patients received 40 or 50 Gy in four fractions. They had three patients with local failure within the SBRT PTV (22/36 pts had intrathoracic failures, most outside SBRT PTV volume) but did not specify if these recurrences were in the 11 patients with previous in-field recurrences. The three failures within the SBRT PTV’s were attributed to compromised tumor coverage (only 22% - 24% of CTV receiving prescribed dose) or to suboptimal dose (40 Gy in 4 fractions).

In our study, all patients had > 90% of the PTV covered with a fractionation scheme resulting in BED of ≥ 100 with the exception on one patient who received 8 Gy x 5 (BED 70). This last patient who had a history of limited stage small cell lung cancer, recurred locally at 11 months as confirmed by a repeat PET scan. Interestingly, this site remained the only site of PET avidity.

5. Conclusions This study suggests that in carefully selected patients who have local recurrence after previous definitive radiation therapy, salvage SBRT may be offered for a durable local control which may lead to a meaningful disease free survival without additional chemotherapy. Further study for SBRT salvage in this setting is being planned.

6. Acknowledgements We would like to thank Drs. Stephen Bader, Christine Cha, Marka Crittenden, David Gannett, Eric Hansen, Jeannie Louie, and Alice Wang-Chesebro for their support.

REFERENCES


Salvage SBRT for Previously Irradiated Lung Cancer


